Biotech entity
funding is the sole category represented across all 1 tracked stories. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Rakovina Therapeutics, all published on February 21, 2026.
Last mentioned: Feb 21, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
funding is the sole category represented across all 1 tracked stories. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Rakovina Therapeutics, all published on February 21, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Closing of Private Placement
Expected completion of the $1.0 million common share offering and debenture issuance.
Financing Upsized
Rakovina announces an increase in its funding round to $2.0 million due to investor demand.
Operational Milestone
Anticipated use of funds for lead candidate advancement or IND-enabling studies.
Rakovina Therapeutics has announced an upsized financing package totaling up to $2.0 million, split between convertible debentures and a private placement. The capital injection is earmarked for near-term operations as the company advances its DNA-damage response (DDR) oncology programs.
Rakovina Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
